title: Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
authors: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul.|Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
authors: S J
authors: SJ
authors: Kim
authors: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul wskimsmc@skku.edu.
authors: W S
authors: WS
authors: Kim
mesh_terms: D047630:Depsipeptides; D020031:Epstein-Barr Virus Infections; D004854:Herpesvirus 4, Human / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell; D016399:Lymphoma, T-Cell; D010865:Pilot Projects; D061988:Proteasome Inhibitors
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D061988:Proteasome Inhibitors; C087123:romidepsin; D006655:Histone Deacetylases